• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较 3 种不同的 A 型肉毒毒素制剂在小鼠体内的药效动力学研究。

Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.

机构信息

Gwanggyo R&D Center, Medytox Inc., Suwon-si, Republic of Korea.

Osong R&D Center, Medytox Inc., Cheonju-si, Republic of Korea.

出版信息

Dermatol Surg. 2020 Dec;46(12):e132-e138. doi: 10.1097/DSS.0000000000002402.

DOI:10.1097/DSS.0000000000002402
PMID:32251006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7685929/
Abstract

BACKGROUND

A new complexing protein-free botulinum toxin Type A (CBoNT) with the same mechanism of action as the botulinum toxin complex onabotulinumtoxinA (OBoNT) and complexing protein-free incobotulinumtoxinA (IBoNT) was recently developed.

OBJECTIVE

To compare the local paresis and chemodenervation efficacy of 3 different botulinum toxin Type A preparations in mice.

MATERIALS AND METHODS

Efficacy and duration of action of CBoNT, OBoNT, and IBoNT after a single intramuscular injection to the right gastrocnemius was evaluated by digit abduction score (DAS) and compound muscle action potential (CMAP) assays.

RESULTS

Mouse DAS and CMAP responses were comparable between CBoNT and OBoNT, indicating similar paresis and chemodenervation efficacy, as well as duration of action. Both botulinum toxins showed significantly higher efficacy and longer duration of action than IBoNT. Similarly, mean DAS potency of CBoNT (ED50: 3.85 ± 0.34 U/kg) and OBoNT (ED50: 4.13 ± 0.07 U/kg) were significantly higher compared with IBoNT (ED50: 6.70 ± 0.83 U/kg).

CONCLUSION

CBoNT displays the same efficacy as OBoNT as shown by their comparable chemodenervation and local paretic effects, and demonstrates superior efficacy and duration of action compared with IBoNT. Likewise, CBoNT has comparable DAS potency to OBoNT and is superior to IBoNT.

摘要

背景

最近开发了一种与肉毒毒素复合物 onabotulinumtoxinA(OBoNT)和无复合物的 incobotulinumtoxinA(IBoNT)具有相同作用机制的新型无复合蛋白肉毒毒素 A 型(CBoNT)。

目的

比较 3 种不同肉毒毒素 A 制剂在小鼠中的局部瘫痪和化学去神经作用效果。

材料和方法

通过数字外展评分(DAS)和复合肌肉动作电位(CMAP)测定,评估 CBoNT、OBoNT 和 IBoNT 单次肌肉内注射右侧比目鱼肌后的疗效和作用持续时间。

结果

CBoNT 和 OBoNT 的小鼠 DAS 和 CMAP 反应相当,表明瘫痪和化学去神经作用效果以及作用持续时间相似。两种肉毒毒素的疗效均明显高于 IBoNT,作用持续时间也更长。同样,CBoNT(ED50:3.85±0.34 U/kg)和 OBoNT(ED50:4.13±0.07 U/kg)的平均 DAS 效价也明显高于 IBoNT(ED50:6.70±0.83 U/kg)。

结论

CBoNT 显示出与 OBoNT 相同的疗效,其化学去神经和局部瘫痪作用相当,与 IBoNT 相比,其疗效和作用持续时间更优。同样,CBoNT 的 DAS 效价与 OBoNT 相当,优于 IBoNT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/091427be40df/ds-46-e132-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/f45ad8093de4/ds-46-e132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/960ec4b0b2ed/ds-46-e132-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/091427be40df/ds-46-e132-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/f45ad8093de4/ds-46-e132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/960ec4b0b2ed/ds-46-e132-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d98/7685929/091427be40df/ds-46-e132-g003.jpg

相似文献

1
Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.比较 3 种不同的 A 型肉毒毒素制剂在小鼠体内的药效动力学研究。
Dermatol Surg. 2020 Dec;46(12):e132-e138. doi: 10.1097/DSS.0000000000002402.
2
Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.三种不同型肉毒毒素制剂在小鼠肌肉内重复给药后的比较药效动力学。
Toxins (Basel). 2022 May 25;14(6):365. doi: 10.3390/toxins14060365.
3
OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.A型肉毒毒素的生物学活性大于注射用A型肉毒梭菌神经毒素,在体外和体内检测中均显示不可互换性。
Toxins (Basel). 2020 Jun 13;12(6):393. doi: 10.3390/toxins12060393.
4
Comparative study of biological activity of four botulinum toxin type A preparations in mice.四种 A 型肉毒毒素制剂在小鼠体内生物活性的比较研究。
Dermatol Surg. 2013 Jan;39(1 Pt 2):155-64. doi: 10.1111/dsu.12071.
5
The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.大鼠足趾外展评分(DAS)测定法:一种评估肉毒神经毒素引起的骨骼肌麻痹的生理模型。
Toxicon. 2013 Sep;71:18-24. doi: 10.1016/j.toxicon.2013.05.004. Epub 2013 May 23.
6
Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit.重组及储存的A型肉毒杆菌毒素的疗效:一项在兔耳肌中的电生理及视觉研究
Plast Reconstr Surg. 2003 Jun;111(7):2419-26; discussion 2427-31. doi: 10.1097/01.PRS.0000061003.68203.56.
7
Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.肉毒杆菌神经毒素A和B型制剂在肌肉弱化功效和全身安全性的临床前模型中具有不同的安全边际。
Toxicon. 2002 Jul;40(7):923-8. doi: 10.1016/s0041-0101(02)00086-7.
8
A pharmacodynamic comparison study of different botulinum toxin type A preparations.不同型肉毒毒素制剂的药效学比较研究。
Dermatol Surg. 2013 Jan;39(1 Pt 2):150-4. doi: 10.1111/dsu.12070.
9
Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.两种不同 BoNT/A 衍生制剂的效力和抗原性的比较评估。
J Neural Transm (Vienna). 2013 Feb;120(2):291-8. doi: 10.1007/s00702-012-0854-3. Epub 2012 Jul 29.
10
Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.不含复合蛋白的A型肉毒杆菌毒素(NT 201)与市售A型肉毒杆菌毒素(保妥适)在健康志愿者中的疗效和耐受性比较。
J Neural Transm (Vienna). 2005 Jul;112(7):905-13. doi: 10.1007/s00702-004-0234-8. Epub 2004 Nov 3.

引用本文的文献

1
A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA.一项比较A型肉毒杆菌毒素和普拉博毒素活性及效力的临床前研究。
Clin Cosmet Investig Dermatol. 2023 Mar 8;16:581-591. doi: 10.2147/CCID.S397999. eCollection 2023.
2
Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.三种不同型肉毒毒素制剂在小鼠肌肉内重复给药后的比较药效动力学。
Toxins (Basel). 2022 May 25;14(6):365. doi: 10.3390/toxins14060365.
3
Dynamic muscle paralytic effects of a novel botulinum toxin A free of neurotoxin-associated proteins.

本文引用的文献

1
Immunogenicity Associated with Botulinum Toxin Treatment.与肉毒毒素治疗相关的免疫原性。
Toxins (Basel). 2019 Aug 26;11(9):491. doi: 10.3390/toxins11090491.
2
Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?为什么产肉毒杆菌神经毒素的细菌如此多样,而肉毒神经毒素又如此致命?
Toxins (Basel). 2019 Jan 11;11(1):34. doi: 10.3390/toxins11010034.
3
A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
新型无神经毒素相关蛋白的肉毒毒素 A 的动态肌肉麻痹作用。
Pharmacol Res Perspect. 2022 Jun;10(3):e00955. doi: 10.1002/prp2.955.
4
Immunogenicity of botulinum toxin.肉毒杆菌毒素的免疫原性。
Arch Plast Surg. 2022 Jan;49(1):12-18. doi: 10.5999/aps.2021.00766. Epub 2022 Jan 15.
5
Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice.A型肉毒杆菌神经毒素对同基因黑色素瘤小鼠的基于模型的抗癌作用
Front Pharmacol. 2022 Jan 4;12:793349. doi: 10.3389/fphar.2021.793349. eCollection 2021.
6
Safety verification for polysorbate 20, pharmaceutical excipient for intramuscular administration, in Sprague-Dawley rats and New Zealand White rabbits.聚山梨酯 20 的安全性验证,用于肌肉注射的药物赋形剂,在 Sprague-Dawley 大鼠和新西兰白兔中的研究。
PLoS One. 2021 Aug 27;16(8):e0256869. doi: 10.1371/journal.pone.0256869. eCollection 2021.
7
OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.A型肉毒毒素的生物学活性大于注射用A型肉毒梭菌神经毒素,在体外和体内检测中均显示不可互换性。
Toxins (Basel). 2020 Jun 13;12(6):393. doi: 10.3390/toxins12060393.
比较了在体外、离体和体内环境下,市售纯化天然肉毒神经毒素血清型 A1 到 F1 的生物活性。
Pharmacol Res Perspect. 2018 Nov 22;6(6):e00446. doi: 10.1002/prp2.446. eCollection 2018 Dec.
4
New trends in botulinum toxin use in dermatology.肉毒杆菌毒素在皮肤科应用的新趋势。
Dermatol Pract Concept. 2018 Oct 31;8(4):277-282. doi: 10.5826/dpc.0804a05. eCollection 2018 Oct.
5
Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.抗体导致肉毒毒素治疗失败:使用低抗原性药物重新开始治疗提供了新的治疗机会。
J Neural Transm (Vienna). 2018 Oct;125(10):1481-1486. doi: 10.1007/s00702-018-1911-3. Epub 2018 Jul 31.
6
Botulinum neurotoxin formulations: overcoming the confusion.肉毒杆菌神经毒素制剂:消除混淆
Clin Cosmet Investig Dermatol. 2018 May 30;11:273-287. doi: 10.2147/CCID.S156851. eCollection 2018.
7
Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.各种肉毒杆菌毒素制剂的药理学差异及临床意义:批判性评价
Funct Neurol. 2018 Jan/Mar;33(1):7-18. doi: 10.11138/fneur/2018.33.1.007.
8
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.肉毒杆菌神经毒素:生物学、药理学与毒理学
Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658.
9
In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.因卡波糖毒素A、肉毒杆菌毒素A和阿泊糖毒素A神经毒性效力的体内比较。
Neurosci Lett. 2016 Aug 3;627:216-21. doi: 10.1016/j.neulet.2016.06.001. Epub 2016 Jun 3.
10
A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.A型肉毒毒素、阿柏型肉毒毒素和因卡型肉毒毒素的定量分析:一项比较动态应变降低的随机、双盲、前瞻性临床试验
Plast Reconstr Surg. 2016 May;137(5):1424-1433. doi: 10.1097/PRS.0000000000002076.